Nature Cancer：恒瑞乳腺癌新药达尔西利最新临床数据发布
Merged summary
TL;DR - A multicenter phase 2 trial found dalpiciclib plus endocrine therapy achieved a 92.5% six-month survival rate in women with HR+/HER2− advanced breast cancer and visceral crisis. The results support further study of this combination in a critically ill population with limited evidence-based treatment options.
- Among 53 participants, 49 survived beyond six months, meeting the primary endpoint.
- Objective response and disease control rates were 26.4% and 79.2%, respectively; median progression-free survival was 11.2 months.
- The most common grade 3 or higher adverse events were decreased neutrophil counts (77.4%) and white blood cell counts (54.7%).
- An exploratory circulating cell-free DNA marker was associated with poorer overall survival, suggesting a potential “molecular crisis” indicator.
Sources (1)
Nature Cancer：恒瑞乳腺癌新药达尔西利最新临床数据发布
TL;DR - A multicenter phase 2 trial found dalpiciclib plus endocrine therapy achieved a 92.5% six-month survival rate in women with HR+/HER2− advanced breast cancer and visceral crisis. The results support further study of this combination in a critically ill population with limited evidence-based treatment options.
- Among 53 participants, 49 survived beyond six months, meeting the primary endpoint.
- Objective response and disease control rates were 26.4% and 79.2%, respectively; median progression-free survival was 11.2 months.
- The most common grade 3 or higher adverse events were decreased neutrophil counts (77.4%) and white blood cell counts (54.7%).
- An exploratory circulating cell-free DNA marker was associated with poorer overall survival, suggesting a potential “molecular crisis” indicator.